Table 1.

Characteristics at entry to the NSABP STAR Trial (P-2) for women included in the STAR-update analyses

Participant characteristicsTamoxifenRaloxifene
No.%No.%
Age (years)
    ≤498849.18789.0
    50–594,85649.94,85549.8
    60–693,13732.23,17432.5
    ≥708598.88478.7
Race/ethnicity
    White9,10593.59,11593.4
    African-American2332.42432.5
    Hispanic1922.01932.0
    Other2062.12032.1
No. 1° relatives with breast cancer
    02,83829.12,79128.6
    15,04651.85,13552.6
    21,53215.71,56116.0
    ≥33203.32672.7
History of hysterectomy
    No4,73948.74,71748.4
    Yes4,99751.35,03751.6
History of lobular carcinoma in situ
    No8,84490.88,86590.9
    Yes8929.28899.1
History of breast atypical hyperplasia
    No7,54577.57,51377.0
    Yes2,19122.52,24123.0
5-year predicted breast cancer risk (%)*
    ≤2.001,05510.81,10211.3
    2.01-3.002,99330.72,89329.7
    3.01-5.003,04231.23,08631.6
    ≥5.012,64627.22,67327.4
Total9,736100.09,754100.0

Abbreviation: NSABP STAR, National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene.

  • *Determined by the Gail model.